Affiliation:
1. MRC Centre for Drug Safety Science and The Wolfson Centre for Personalised Medicine, Department of Pharmacology & Therapeutics, University of Liverpool Liverpool UK sudeepp@liverpool.ac.uk
Abstract
Despite increasing investments and an improved understanding of disease, the pharmaceutical industry has failed to translate these into credible therapeutic outputs. This has resulted in a need for innovative approaches like drug repurposing to treat both common and rare diseases. Some of the earliest examples of repurposing relied on serendipity and retrospective clinical experience, leading to the successful repurposing of previously failed drugs such as thalidomide and sildenafil in multiple disease conditions. However, modern repurposing approaches tap into an ever-increasing wealth of drug- and disease-related data, computationally driven hypothesis generation and high throughput screening methods for the identification of newer uses for existing drugs. This book discusses some of the most widely used approaches in drug repurposing and the major stakeholders involved; it also highlights various challenges and suggests innovative solutions to take forward.
Publisher
The Royal Society of Chemistry
Reference40 articles.
1. Dexamethasone in hospitalized patients with Covid-19;The RECOVERY Collaborative Group;N. Engl. J. Med.,2021
2. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis,2020
3. Drug repositioning: identifying and developing new uses for existing drugs;Ashburn;Nat. Rev. Drug Discovery,2004
4. Can you teach old drugs new tricks?;Nosengo;Nature,2016
5. Diagnosing the decline in pharmaceutical R&D efficiency;Scannell;Nat. Rev. Drug Discovery,2012
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献